SA515361104B1 - مشتقات بيريدين-4-يل - Google Patents

مشتقات بيريدين-4-يل Download PDF

Info

Publication number
SA515361104B1
SA515361104B1 SA515361104A SA515361104A SA515361104B1 SA 515361104 B1 SA515361104 B1 SA 515361104B1 SA 515361104 A SA515361104 A SA 515361104A SA 515361104 A SA515361104 A SA 515361104A SA 515361104 B1 SA515361104 B1 SA 515361104B1
Authority
SA
Saudi Arabia
Prior art keywords
hydroxyacetamide
hydroxypropyl
methylphenoxy
ethyl
diseases
Prior art date
Application number
SA515361104A
Other languages
Arabic (ar)
English (en)
Inventor
مارتين بولى،
بيات ستينر،
كيريل ليسكوب،
اوليفر نايلر،
Original Assignee
اكتيليون فارماسوتيكالز ال تي دي
ايدورسيا فارماسوتيكالز ليمتد
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by اكتيليون فارماسوتيكالز ال تي دي, ايدورسيا فارماسوتيكالز ليمتد filed Critical اكتيليون فارماسوتيكالز ال تي دي
Publication of SA515361104B1 publication Critical patent/SA515361104B1/ar

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
SA515361104A 2013-03-15 2015-09-14 مشتقات بيريدين-4-يل SA515361104B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13159482 2013-03-15
PCT/IB2014/059794 WO2014141171A1 (en) 2013-03-15 2014-03-14 Pyridin-4-yl derivatives

Publications (1)

Publication Number Publication Date
SA515361104B1 true SA515361104B1 (ar) 2016-06-28

Family

ID=47877933

Family Applications (1)

Application Number Title Priority Date Filing Date
SA515361104A SA515361104B1 (ar) 2013-03-15 2015-09-14 مشتقات بيريدين-4-يل

Country Status (33)

Country Link
US (1) US9617250B2 (OSRAM)
EP (1) EP2970236B1 (OSRAM)
JP (1) JP6387361B2 (OSRAM)
KR (1) KR102212975B1 (OSRAM)
CN (1) CN105189487B (OSRAM)
AR (1) AR095523A1 (OSRAM)
AU (1) AU2014229217B2 (OSRAM)
BR (1) BR112015023161B1 (OSRAM)
CA (1) CA2900910C (OSRAM)
CL (1) CL2015002620A1 (OSRAM)
CY (1) CY1119619T1 (OSRAM)
DK (1) DK2970236T3 (OSRAM)
EA (1) EA029309B1 (OSRAM)
ES (1) ES2649475T3 (OSRAM)
HR (1) HRP20171763T1 (OSRAM)
HU (1) HUE035154T2 (OSRAM)
IL (1) IL241363B (OSRAM)
LT (1) LT2970236T (OSRAM)
MA (1) MA38482B1 (OSRAM)
MX (1) MX363545B (OSRAM)
MY (1) MY173573A (OSRAM)
NO (1) NO2970236T3 (OSRAM)
NZ (1) NZ713080A (OSRAM)
PH (1) PH12015502118B1 (OSRAM)
PL (1) PL2970236T3 (OSRAM)
PT (1) PT2970236T (OSRAM)
SA (1) SA515361104B1 (OSRAM)
SG (1) SG11201507227UA (OSRAM)
SI (1) SI2970236T1 (OSRAM)
TW (1) TWI623534B (OSRAM)
UA (1) UA115357C2 (OSRAM)
WO (1) WO2014141171A1 (OSRAM)
ZA (1) ZA201507657B (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6437452B2 (ja) 2013-01-14 2018-12-12 インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation Pimキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物
LT2945939T (lt) 2013-01-15 2020-07-27 Incyte Holdings Corporation Triazolkarboksamidai ir piridinkarboksamido junginiai, naudotini kaip pim kinazės inhibitoriai
EP3036238A1 (en) 2013-08-23 2016-06-29 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
EP3298008B1 (en) 2015-05-20 2019-11-20 Idorsia Pharmaceuticals Ltd Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
WO2017004610A1 (en) * 2015-07-02 2017-01-05 Exelixis, Inc. Tercyclic s1p3-sparing, s1p1 receptor agonists
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7686891A (en) 1990-04-05 1991-10-30 American National Red Cross, The A protein family related to immediate-early protein expressed by human endothelial cells during differentiation
EP1070080A4 (en) 1998-03-09 2004-12-29 Smithkline Beecham Corp HUMAN EDG-1c POLYNUCLEOTIDES AND POLYPEPTIDES AND THEIR APPLICATIONS
AU2003279915A1 (en) 2002-10-15 2004-05-04 Merck And Co., Inc. Process for making azetidine-3-carboxylic acid
MY149853A (en) * 2006-09-07 2013-10-31 Actelion Pharmaceuticals Ltd Pyridin-4-yl derivatives as immunomodulating agents
AR062684A1 (es) 2006-09-08 2008-11-26 Actelion Pharmaceuticals Ltd Compuestos derivados de piridin-3- ilo, composicion farmaceutica que los contiene, y uso de los mismos en la preparacion de medicamentos
JP5250556B2 (ja) 2006-09-21 2013-07-31 アクテリオン ファーマシューティカルズ リミテッド フェニル誘導体及びそれらの免疫調節薬としての使用
DK2125797T3 (da) 2007-03-16 2014-02-10 Actelion Pharmaceuticals Ltd Aminopyridinderivater som s1p1/edg1-receptoragonister
HRP20110449T1 (hr) 2007-08-17 2011-07-31 Actelion Pharmaceuticals Ltd. Derivati piridina kao modulatori receptora s1p1/edg1
EP2193125B1 (en) 2007-10-04 2017-01-11 Merck Serono S.A. Oxadiazole derivatives
ES2449749T3 (es) 2007-11-01 2014-03-21 Actelion Pharmaceuticals Ltd. Nuevos derivados de pirimidina
CA2714665A1 (en) 2008-03-06 2009-09-11 Actelion Pharmaceuticals Ltd Pyridine compounds
US20110046170A1 (en) 2008-03-06 2011-02-24 Martin Bolli Novel pyrimidine-pyridine derivatives
KR20100125380A (ko) 2008-03-07 2010-11-30 액테리온 파마슈티칼 리미티드 신규한 아미노메틸 벤젠 유도체
JP5435745B2 (ja) * 2008-03-07 2014-03-05 アクテリオン ファーマシューティカルズ リミテッド 免疫調節剤としてのピリジン−2−イル誘導体
PL2291080T3 (pl) * 2008-05-14 2015-12-31 Scripps Research Inst Nowe modulatory receptorów sfingozyno-1-fosforanu
WO2010100142A1 (en) 2009-03-03 2010-09-10 Merck Serono S.A. Oxazole pyridine derivatives useful as s1p1 receptor agonists
KR101409131B1 (ko) 2009-07-16 2014-06-17 액테리온 파마슈티칼 리미티드 피리딘-4-일 유도체
TW201120016A (en) 2009-12-08 2011-06-16 Abbott Lab Novel oxadiazole compounds
WO2012098505A1 (en) 2011-01-19 2012-07-26 Actelion Pharmaceuticals Ltd 2-methoxy-pyridin-4-yl derivatives

Also Published As

Publication number Publication date
CL2015002620A1 (es) 2016-03-18
SG11201507227UA (en) 2015-10-29
EA201500931A1 (ru) 2016-03-31
DK2970236T3 (en) 2017-10-16
WO2014141171A1 (en) 2014-09-18
PL2970236T3 (pl) 2018-01-31
US9617250B2 (en) 2017-04-11
AR095523A1 (es) 2015-10-21
KR102212975B1 (ko) 2021-02-05
EP2970236B1 (en) 2017-08-30
ZA201507657B (en) 2022-08-31
BR112015023161B1 (pt) 2022-11-16
TWI623534B (zh) 2018-05-11
BR112015023161A2 (pt) 2017-07-18
BR112015023161A8 (pt) 2021-06-22
CY1119619T1 (el) 2018-04-04
CA2900910A1 (en) 2014-09-18
KR20150128947A (ko) 2015-11-18
AU2014229217B2 (en) 2017-12-14
PT2970236T (pt) 2017-11-30
MY173573A (en) 2020-02-04
EA029309B1 (ru) 2018-03-30
PH12015502118A1 (en) 2016-01-25
MX363545B (es) 2019-03-27
IL241363A0 (en) 2015-11-30
EP2970236A1 (en) 2016-01-20
AU2014229217A1 (en) 2015-11-05
PH12015502118B1 (en) 2016-01-25
US20160031866A1 (en) 2016-02-04
CA2900910C (en) 2021-03-30
MA38482B1 (fr) 2018-11-30
TW201443044A (zh) 2014-11-16
HRP20171763T1 (hr) 2017-12-29
IL241363B (en) 2018-11-29
LT2970236T (lt) 2017-11-10
CN105189487A (zh) 2015-12-23
HUE035154T2 (en) 2018-05-02
JP2016512227A (ja) 2016-04-25
SI2970236T1 (sl) 2017-11-30
CN105189487B (zh) 2017-12-26
UA115357C2 (uk) 2017-10-25
ES2649475T3 (es) 2018-01-12
NZ713080A (en) 2020-06-26
JP6387361B2 (ja) 2018-09-05
MX2015012293A (es) 2015-12-16
NO2970236T3 (OSRAM) 2018-01-27
MA38482A1 (fr) 2017-12-29
HK1220454A1 (en) 2017-05-05

Similar Documents

Publication Publication Date Title
SA515361104B1 (ar) مشتقات بيريدين-4-يل
EP3712153B1 (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
JP5036923B1 (ja) ピリジン−4−イル誘導体
MXPA05002644A (es) Derivados de pirimidinona como agentes terapeuticos contra procesos de remodelacion, isquemicos e inflamatorios agudos y cronicos.
JP2009543836A (ja) インドール化合物
EP4332102A1 (en) Isoquinolone compound and use thereof
JP2009543838A (ja) インドール化合物
EP3846809A1 (en) 2,6-diamino pyridine compounds
JP2009543837A (ja) Ep1受容体に対して親和性を有するインドール化合物
EP2665720B1 (en) 2-methoxy-pyridin-4-yl derivatives
EA023238B1 (ru) Замещенные производные индола для лечения иммунологических расстройств
CN108947974B (zh) 一种氨基嘧啶类化合物及包含该化合物的组合物及其用途
KR20220016223A (ko) Rip-1 키나아제 억제제인 바이사이클릭 화합물 및 이의 응용
WO2024012425A1 (zh) 作为ripk1抑制剂的杂环化合物
TW202411221A (zh) 一種三嗪二酮類衍生物的晶型及製備方法
CN120590460A (zh) Vhl类衍生物及其在制备smarca2降解剂中的用途
HK1220454B (en) Pyridin-4-yl derivatives
WO2010005385A1 (en) 2-amino-6-alkyl substituted pyridine derivatives useful as p2y12 inhibitors 308
HK40052052A (en) Novel lxr modulators with bicyclic core moiety
HK40052052B (en) Novel lxr modulators with bicyclic core moiety
BR112018015501B1 (pt) Derivados de pirazolo[1,5-a]pirazin-4-ila como inibidores de jak, seu uso e composição farmacêutica que os compreende
HK1191645B (en) 2-methoxy-pyridin-4-yl derivatives